Canbridge Pharmaceuticals (HKSE:01228) Operating Margin %: -180.07% (As of Dec. 2025)


HKSE:01228 Canbridge Pharmaceuticals Inc HKSE:01228
46 GF Score
Price HK$2.70
GF Value HK$0.38
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Canbridge Pharmaceuticals Operating Margin %?

Canbridge Pharmaceuticals HKSE:01228 +35.68% 46 Operating Margin % is -180.07% as of Dec. 2025. GuruFocus rates HKSE:01228 with a GF Score™ of 46/100 and a GF Value™ of HK$0.38 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 941 Biotechnology companies, Canbridge Pharmaceuticals ranks worse than 58.02% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Canbridge Pharmaceuticals's Operating Income for the six months ended in Dec. 2025 was HK$-55.17 Mil. Canbridge Pharmaceuticals's Revenue for the six months ended in Dec. 2025 was HK$30.64 Mil. Therefore, Canbridge Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2025 was -180.07%.

Good Sign:

Canbridge Pharmaceuticals Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Canbridge Pharmaceuticals's Operating Margin % or its related term are showing as below:

HKSE:01228' s Operating Margin % Range Over the Past 10 Years
Min: -9313.39   Med: -569.21   Max: -183.17
Current: -183.17


HKSE:01228's Operating Margin % is ranked worse than
58.02% of 941 companies
in the Biotechnology industry
Industry Median: -86.89 vs HKSE:01228: -183.17

Canbridge Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 38.80% per year.

Canbridge Pharmaceuticals's Operating Income for the six months ended in Dec. 2025 was HK$-55.17 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-100.67 Mil.


Canbridge Pharmaceuticals  (HKSE:01228) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Canbridge Pharmaceuticals Operating Margin % Related Terms


Canbridge Pharmaceuticals Operating Margin % Historical Data

* Premium members only.

The historical data trend for Canbridge Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Canbridge Pharmaceuticals Operating Margin % Chart

Canbridge Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -2,101.14 -569.21 -354.92 -399.29 -183.19

Canbridge Pharmaceuticals Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -271.31 -489.48 -299.06 -187.08 -180.07

HKSE:01228 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Canbridge Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Canbridge Pharmaceuticals Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Canbridge Pharmaceuticals's Operating Margin % falls into.


HKSE:01228
46GF Score
Canbridge Pharmaceuticals Inc HKSE:01228
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Canbridge Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Canbridge Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-101.154 / 55.217
=-183.19 %

Canbridge Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-55.174 / 30.64
=-180.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -180.07% mean?
Canbridge Pharmaceuticals (HKSE:01228) has a Operating Margin % of -180.07% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Canbridge Pharmaceuticals and its competitors. According to the industry distribution chart, Canbridge Pharmaceuticals ranks #546 out of 941 companies in the Biotechnology industry, placing it in the top 58%.
Is Canbridge Pharmaceuticals' Operating Margin % too high?
Canbridge Pharmaceuticals' current Operating Margin % is -180.07%. Based on the distribution chart, Canbridge Pharmaceuticals ranks #546 out of 941 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Canbridge Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Canbridge Pharmaceuticals ranks #546 out of 941 companies for Operating Margin %. This places Canbridge Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Canbridge Pharmaceuticals and its competitors. Canbridge Pharmaceuticals's current Operating Margin % is -180.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals (HKSE:01228) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.38, compared to a current price of HK$2.70 — trading 610.5% above its estimated fair value. The current Operating Margin % is -180.07%. Canbridge Pharmaceuticals' overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Canbridge Pharmaceuticals (HKSE:01228), the current Operating Margin % is -180.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Canbridge Pharmaceuticals (HKSE:01228) Overvalued in 2026?

Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued. The current stock price of HK$2.70 is trading 610.5% above its estimated GF Value™ of HK$0.38. GuruFocus considers Canbridge Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for HKSE:01228:

  • Operating Margin %: -180.07%
  • GF Value™: HK$0.38 vs. price of HK$2.70 (610.5% above fair value)
  • GF Score™: 46/100 with 7 warning signs

No single metric tells the full story. See the HKSE:01228 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Canbridge Pharmaceuticals Business Description

Address No. 388 Xinping Street, Unit 9, 10th Floor, Building 21, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
46GF Score

Get the complete analysis for HKSE:01228

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.70
Price
HK$0.38
GF Value